Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab ; volume:11 ; number:4 ; day:14 ; month:5 ; year:2021 ; pages:1265-1275 ; date:8.2021
Dermatology and therapy ; 11, Heft 4 (14.5.2021), 1265-1275, 8.2021
- Urheber
-
Lambert, Jo
Hansen, Jes Birger
Sohrt, Anne
Puig, Luis
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-021-00545-5
- URN
-
urn:nbn:de:101:1-2021102718543042670458
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lambert, Jo
- Hansen, Jes Birger
- Sohrt, Anne
- Puig, Luis
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)